PDCD1 and neoplasm: Combined blockade of TGFβ and anti-PD-1 in MM has been shown to promote anti-tumor T cell activation and proliferation, indicating that targeting the different immunosuppressive pathways occurring in the TME can reactivate endogenous anti-tumor immune responses and favor tumor clearance (287).